skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 448  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
Material Type:
Article 		Add to My Research

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

The lancet oncology, 2018-01, Vol.19 (1), p.27-39 [Peer Reviewed Journal]

2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;COPYRIGHT 2018 Elsevier B.V. ;Copyright Elsevier Limited Jan 1, 2018 ;2018. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2018 ;ISSN: 1470-2045 ;ISSN: 1474-5488 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(17)30777-5 ;PMID: 29242041

Full text available

Citations Cited by
2
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831
Material Type:
Article 		Add to My Research

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831

Journal of clinical oncology, 2014-11, Vol.32 (33), p.3744-3752 [Peer Reviewed Journal]

2014 by American Society of Clinical Oncology. ;2014 by American Society of Clinical Oncology 2014 ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2014.55.5730 ;PMID: 25332249

Full text available

Citations Cited by
3
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials
Material Type:
Article 		Add to My Research

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

The Lancet (British edition), 2019-04, Vol.393 (10179), p.1440-1452 [Peer Reviewed Journal]

2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2019. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. ;2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2019 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(18)33137-4 ;PMID: 30739743

Full text available

Citations Cited by
4
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
Material Type:
Article 		Add to My Research

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

The lancet oncology, 2021-08, Vol.22 (8), p.1139-1150 [Peer Reviewed Journal]

2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2021. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2021 ;ISSN: 1470-2045 ;ISSN: 1474-5488 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00288-6 ;PMID: 34339645

Full text available

Citations Cited by
5
Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses
Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses
Material Type:
Article 		Add to My Research

Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses

Journal of clinical oncology, 2011-10, Vol.29 (28), p.3768-3774 [Peer Reviewed Journal]

2015 INIST-CNRS ;2011 by American Society of Clinical Oncology 2011 ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2011.36.4539 ;PMID: 21859995

Full text available

Citations Cited by
6
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
Material Type:
Article 		Add to My Research

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials

The lancet oncology, 2022-03, Vol.23 (3), p.382-392 [Peer Reviewed Journal]

2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licence ;Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licence. Published by Elsevier Ltd.. All rights reserved. ;2022. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licence. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licence 2022 ;ISSN: 1470-2045 ;ISSN: 1474-5488 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00758-0 ;PMID: 35123662

Full text available

Citations Cited by
7
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Material Type:
Article 		Add to My Research

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

The Lancet (British edition), 2014-07, Vol.384 (9938), p.164-172 [Peer Reviewed Journal]

Elsevier Ltd ;2014 Elsevier Ltd ;Copyright © 2014 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jul 12, 2014 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(13)62422-8 ;PMID: 24529560 ;CODEN: LANCAO

Full text available

Citations Cited by
8
Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27
Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27
Material Type:
Article 		Add to My Research

Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27

Journal of clinical oncology, 2012-11, Vol.30 (32), p.3960-3966 [Peer Reviewed Journal]

2015 INIST-CNRS ;2012 by American Society of Clinical Oncology 2012 ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2011.40.8369 ;PMID: 23032615

Full text available

Citations Cited by
9
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
Material Type:
Article 		Add to My Research

CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer

The New England journal of medicine, 2016-01, Vol.374 (3), p.211-222 [Peer Reviewed Journal]

Copyright © 2016 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1506597 ;PMID: 26789870

Full text available

Citations Cited by
10
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial
Material Type:
Article 		Add to My Research

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial

Journal of clinical oncology, 2019-01, Vol.37 (3), p.178-189 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.18.01624 ;PMID: 30523750

Full text available

Citations Cited by
11
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
Material Type:
Article 		Add to My Research

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

Journal of clinical oncology, 2011-09, Vol.29 (25), p.3366-3373 [Peer Reviewed Journal]

2015 INIST-CNRS ;2011 by American Society of Clinical Oncology 2011 ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2011.35.0868 ;PMID: 21768458

Full text available

Citations Cited by
12
Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03
Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03
Material Type:
Article 		Add to My Research

Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03

Journal of clinical oncology, 2009-11, Vol.27 (31), p.5124-5130 [Peer Reviewed Journal]

2009 INIST-CNRS ;2009 by American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2009.22.0467 ;PMID: 19770376

Full text available

Citations Cited by
13
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)
Material Type:
Article 		Add to My Research

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)

Journal of clinical oncology, 2017-08, Vol.35 (23), p.2647-2655 [Peer Reviewed Journal]

2017 by American Society of Clinical Oncology 2017 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2016.71.4147 ;PMID: 28398846

Full text available

Citations Cited by
14
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial
Material Type:
Article 		Add to My Research

Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial

The lancet oncology, 2010-10, Vol.11 (10), p.927-933 [Peer Reviewed Journal]

Elsevier Ltd ;2010 Elsevier Ltd ;Copyright © 2010 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Oct 2010 ;2010 Elsevier Ltd. All rights reserved. 2010 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(10)70207-2 ;PMID: 20863759 ;CODEN: LANCAO

Full text available

Citations Cited by
15
Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20
Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20
Material Type:
Article 		Add to My Research

Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20

Journal of clinical oncology, 2010-04, Vol.28 (10), p.1677-1683 [Peer Reviewed Journal]

2010 by American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2009.23.7610 ;PMID: 20065188

Full text available

Citations Cited by
16
Effect of Occult Metastases on Survival in Node-Negative Breast Cancer
Effect of Occult Metastases on Survival in Node-Negative Breast Cancer
Material Type:
Article 		Add to My Research

Effect of Occult Metastases on Survival in Node-Negative Breast Cancer

The New England journal of medicine, 2011-02, Vol.364 (5), p.412-421 [Peer Reviewed Journal]

Copyright © 2011 Massachusetts Medical Society. All rights reserved. ;2015 INIST-CNRS ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1008108 ;PMID: 21247310 ;CODEN: NEJMAG

Full text available

Citations Cited by
17
Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Material Type:
Article 		Add to My Research

Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Journal of clinical oncology, 2012-11, Vol.30 (31), p.3792-3799 [Peer Reviewed Journal]

2015 INIST-CNRS ;2012 by American Society of Clinical Oncology 2012 ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2011.40.0010 ;PMID: 22987084

Full text available

Citations Cited by
18
Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
Material Type:
Article 		Add to My Research

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

Journal of clinical oncology, 2011-01, Vol.29 (1), p.11-16 [Peer Reviewed Journal]

2015 INIST-CNRS ;2010 by American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2010.30.0855 ;PMID: 20940184

Full text available

Citations Cited by
19
Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04
Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04
Material Type:
Article 		Add to My Research

Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04

Journal of clinical oncology, 2014-06, Vol.32 (18), p.1927-1934 [Peer Reviewed Journal]

2015 INIST-CNRS ;2014 by American Society of Clinical Oncology. ;2014 by American Society of Clinical Oncology 2014 ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2013.53.7753 ;PMID: 24799484

Full text available

Citations Cited by
20
Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24
Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24
Material Type:
Article 		Add to My Research

Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24

Journal of clinical oncology, 2012-04, Vol.30 (12), p.1268-1273 [Peer Reviewed Journal]

2015 INIST-CNRS ;2012 by American Society of Clinical Oncology 2012 ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2010.34.0141 ;PMID: 22393101

Full text available

Citations Cited by

Results 1 - 20 of 448  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (414)

Refine My Results

Creation Date 

From To
Refine
  1. Before 1985  (15)
  2. 1985 To 1996  (29)
  3. 1997 To 2005  (73)
  4. 2006 To 2015  (161)
  5. After 2015  (171)
  6. More options open sub menu

Language 

  1. English  (443)
  2. Japanese  (59)
  3. French  (10)
  4. German  (3)
  5. Spanish  (3)
  6. Chinese  (2)
  7. Russian  (1)
  8. Arabic  (1)
  9. Korean  (1)
  10. Portuguese  (1)
  11. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait